Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma

Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma

Autor Freitas, Marcelo Roberto Pereira Autor UNIFESP Google Scholar
Malheiros, Suzana Maria Fleury Autor UNIFESP Google Scholar
Stávale, João Norberto Autor UNIFESP Google Scholar
Biassi, Thais Priscila Autor UNIFESP Google Scholar
Zamuner, Fernando Tadeu Autor UNIFESP Google Scholar
Begnami, Maria Dirlei Ferreira de Souza Google Scholar
Soares, Fernando Augusto Google Scholar
Vettore, Andre Luiz Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
AC Camargo Canc Hosp
Resumo Background: Glioblastoma (GBM) confers a dismal prognosis despite advances in current therapy. Cancer-testis antigens (CTA) comprise families of tumor-associated antigens that are immunogenic in different cancers. The aim of this study was to determine the expression profile of a large number of CTA genes in GBM.Methods: We selected, from 153 CTA genes, those genes potentially expressed in GBM. The expression pattern of 30 CTA was then evaluated by RT-PCR in a series of 48 GBM and 5 normal brain samples. The presence of CTCFL protein was also evaluated by immunohistochemical staining.Results: Among the genes with no expression in normal brain, ACTL8 (57%), OIP5 (54%), XAGE3 (44%) and CTCFL (15%) were frequently expressed in GBM, while over 85% of the tumors expressed at least 1 of these four CTA. Coexpression of two or more CTA occurred in 49% of cases. CTCFL protein expression was detected in 13% of the GBM and was negative in normal brain samples. GBM expressing 3-4 CTA was associated with significantly better overall survival (OS) rates (P = 0.017). By multivariate analysis, mRNA positivity for 3-4 CTA (P = 0.044), radiotherapy (P = 0.010) and chemotherapy (P = 0.001) were independent prognostic factors for OS.Conclusions: GBM frequently express ACTL8, OIP5, XAGE3 and CTCFL. A relatively high percentage of tumors expressed at least one of these four CTA, opening the perspective for their utility in antigen-specific immunotherapy. Furthermore, mRNA positivity for 3-4 CTA is an independent predictor of better OS for GBM patients.
Assunto Brain cancer
Glioblastoma
GBM
Cancer/Testis antigens
CTA expression
Idioma Inglês
Financiador Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Número do financiamento FAPESP: 2010/20218/2
Data 2013-04-01
Publicado em Oncotarget. Albany: Impact Journals Llc, v. 4, n. 4, p. 636-646, 2013.
ISSN 1949-2553 (Sherpa/Romeo, fator de impacto)
Editor Impact Journals Llc
Extensão 636-646
Fonte http://dx.doi.org/10.18632/oncotarget.950
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000318783800015
URI http://repositorio.unifesp.br/11600/45064

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)